GFAP and depressive symptom measurement: In summary, this investigation suggests that GFAP-positive astrocyte-specific deletion of GLT1 decreased anxiety- and depression-like behaviors, which may provide novel insights toward the underlying mechanisms of mood related psychiatric disorders.